within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DC04_Ixabepilone;

model Ixabepilone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.277777777777778e-06,
    adminDuration = 600,
    adminMass = 80 / 1000000,
    adminCount = 1,
    Vd = 0.04,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.71,
    k12 = 1.2777777777777777e-05,
    k21 = 1.2777777777777777e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ixabepilone</td></tr><tr><td>ATC code:</td><td>L01DC04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>80</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>40</td><td>L</td></tr>
    <tr><td>clearance:</td><td>19</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ixabepilone is a semisynthetic analog of epothilone B, classified as an antineoplastic agent. It is a microtubule inhibitor used primarily in the treatment of metastatic or locally advanced breast cancer, particularly in cases that are resistant to anthracyclines and taxanes. Ixabepilone is approved for intravenous use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in cancer patients following a single intravenous infusion of 40 mg/m2 over 3 hours.</p><h4>References</h4><ol><li><p>Shimizu, T, et al., &amp; Tamura, T (2008). Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. <i>Cancer chemotherapy and pharmacology</i> 61(5) 751–758. DOI:<a href=\"https://doi.org/10.1007/s00280-007-0530-8\">10.1007/s00280-007-0530-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17594093/\">https://pubmed.ncbi.nlm.nih.gov/17594093</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01DC04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ixabepilone;
